Tag: Jennifer Doudna

4 Gene Therapy Stocks to Watch in 2017

At the halfway mark of 2017, here's a look at how these four gene therapy companies are performing so far...

Thom Calandra: Investing in Gene-editing Stocks

Thom Calandra is known to investors in the resource space. Recently, he wrote about biotechnology and started his own index...

The CRISPR-Cas9 Patent Dispute

The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.

Best Regions for Genetics Research

The US, China and the UK are the top regions for genetics research.

After Hot IPO Editas Medicine Bogged Down by CRISPR/Cas9 Legal Issues

Editas Medicine's share price went on a tear following its IPO in February. In the last two days, however, it's...